Exhibit 99.2

    Interleukin Genetics Updates Status of Filing Annual Report on
            Form 10-K for the Year Ended December 31, 2004

    WALTHAM, Mass.--(BUSINESS WIRE)--April 7, 2005--Interleukin
Genetics, Inc. (OTCBB: ILGN) announced that it is continuing its
review of the accounting treatment of its March 2003 sale of Series A
Convertible Preferred Stock and convertible long-term debt in its
previously reported financial statements for the year ended December
31, 2003 and that the filing of its Annual Report on Form 10-K for the
year ended December 31, 2004 will be further delayed until the
completion of this review. The Company is also reviewing the
accounting treatment of its research and development agreements with
affiliates of Alticor. In connection with this review, the Company
expects to restate its previously reported financial statements for
the year ended December 31, 2003 and anticipates that as a result of
its review some or all of the payments received under those research
and development agreements will be reclassified as payments for equity
rather than revenues. The Company expects to file its Annual Report on
Form 10-K for the year ended December 31, 2004 during the week of
April 11, 2005 and will schedule an investor conference call shortly
thereafter.

    About Interleukin

    Interleukin Genetics is a biotechnology company focused on
developing personalized health products. The company uses functional
genomics to help in the development of risk assessment tests,
pharmacogenetic tests, nutritional and therapeutic products based on
the genetic variations in people. Interleukin's current programs focus
on cardiovascular disease, osteoporosis, rheumatoid arthritis,
endometriosis, periodontal disease and weight management. Interleukin
expects that these programs will lead to products that will
personalize the selection of nutritional and therapeutic products and
enable the managed care industry to improve patient care and better
allocate resources. For more information about Interleukin and its
ongoing programs, please visit http://www.ilgenetics.com.

    Certain statements contained herein are "forward-looking"
statements including statements regarding the restatement of our
financial statements for the year ended December 31, 2003. Because
such statements include risks and uncertainties, actual results may
differ materially from those expressed or implied by such
forward-looking statements. Factors that could cause actual results to
differ materially from those expressed or implied by such
forward-looking statements include, but are not limited to, the
results of our review of the accounting treatment of the March 2003
transactions and research and development agreements and those risks
and uncertainties described in our annual report on Form 10-K, our
quarterly reports on Form 10-Q and in other filings made by us with
the Securities and Exchange Commission. We disclaim any obligation or
intention to update these forward-looking statements.

    CONTACT: For Interleukin Genetics:
             Fenel M. Eloi, 781-398-0700